# How to Treat Severe Lung Infections Using Ceftolozane and Tazobactam

> A medical treatment method for severe, hospital-acquired pneumonia using a specific, recurring intravenous dose of the antibiotic combination ceftolozane and tazobactam.

- **Patent:** US 10028963
- **Original title:** Methods for treating intrapulmonary infections
- **Owner:** Merck Sharp and Dohme LLC
- **Granted:** 2018
- **Status:** Active
- **Times cited:** 0
- **Field:** biotech, pharmaceutical

## What it does

The patent outlines a specific medical regimen for treating pneumonia, particularly infections acquired in hospital settings or via ventilators. It requires the intravenous administration of 2.0 grams of the antibiotic ceftolozane, combined with tazobactam, every 8 hours. The claims specify that this infusion should last for 60 minutes to be effective against common, stubborn pathogens like Pseudomonas aeruginosa, E. coli, and K. pneumoniae.

## What it does NOT cover

- Does not cover oral administration of these antibiotics.
- Does not cover dosages other than the specified 2.0 grams of ceftolozane.
- Does not cover treatment regimens administered at intervals other than every 8 hours.
- Does not cover the chemical synthesis of the drugs themselves.

## The clever bit

The innovation lies in identifying the precise 'pharmacokinetic window'—the specific dose and 8-hour frequency—that maintains enough of the drug in the lungs to effectively kill resistant bacteria without causing toxicity.

## Real-world examples

1. Zerbaxa (a commercial antibiotic product containing ceftolozane and tazobactam)

## Why it matters

This patent protects a specific clinical dosing protocol for a potent antibiotic combination. By defining the exact dosage and timing required to fight resistant hospital-acquired pneumonia, it provides a clear legal framework for how this medication is prescribed and marketed in clinical settings.

## Frequently asked questions

### What does How to Treat Severe Lung Infections Using Ceftolozane and Tazobactam cover?

A medical treatment method for severe, hospital-acquired pneumonia using a specific, recurring intravenous dose of the antibiotic combination ceftolozane and tazobactam.

### Who owns patent US 10028963?

Merck Sharp and Dohme LLC owns this patent, granted in 2018.

### When does this patent expire?

This patent is expected to expire on July 24, 2038, when the invention enters the public domain.

### What problem does this patent solve?

This patent protects a specific clinical dosing protocol for a potent antibiotic combination. By defining the exact dosage and timing required to fight resistant hospital-acquired pneumonia, it provides a clear legal framework for how this medication is prescribed and marketed in clinical settings.

### What does this patent NOT cover?

Does not cover oral administration of these antibiotics.

**Full plain-English explainer:** https://patentbrief.org/patent/us/10028963/biktarvy-bictegravir-taf-ftc

**Original patent:** https://patents.google.com/patent/US10028963

---

_Source: PatentBrief — https://patentbrief.org. Patent facts are from public records; the plain-English explanation is PatentBrief's._